Journal of Vascular Nursing
Volume 26, Issue 4 , Pages 118-122 , December 2008

Nurse-led risk assessment/management clinics reduce predicted cardiac morbidity and mortality in claudicants

References 

  1. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384–392
  2. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999;12:123–137
  3. Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R. Joint British Recommendations on prevention of coronary heart disease in clinical practice. Heart. 1998;80(Suppl. 2):S1–S29
  4. Richardson G, van Woerden HC, Morgan L, Edwards R, Harries M, Hancock E, et al. Healthy hearts - a community based primary prevention programme to reduce coronary heart disease. BMC Cardiovascular Disorders. 2008;8:8–18
  5. D'Agostino RB, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180–187
  6. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–331
  7. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12:209–215
  8. Cassar K, Belch JJ, Brittenden J. Are national cardiac guidelines being applied by vascular surgeons?. Eur J Vasc Endovasc Surg. 2003;26:623–628
  9. Cassar K, Coull R, Bachoo P, Macaulay E, Brittenden J. Management of secondary risk factors in patients with intermittent claudication. Eur J Vasc Endovasc Surg. 2003;26:262–266
  10. Sol BG, van der Bijl JJ, Banga JD, Visseren FL. Vascular risk management through nurse-led self-management programs. J Vasc Nurs. 2005;23:20–24
  11. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest. 2000;117:758–763
  12. Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the Vascular Quality of Life Questionnaire: a new disease-specific quality of life measure for use in lower limb ischemia. J Vasc Surg. 2001;33:679–687
  13. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  14. Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Health Education Authority. Thorax. 1998;53(Suppl 5):S1–S19
  15. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000;283:3244–3254
  16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  17. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853
  20. Tierney S, Fennessy F, Hayes DB. ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ. 2000;320:1262–1265
  21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  22. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart. 1999;81:40–46
  23. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181:93–100
  24. Coughlin PA, Gulati V, Mavor AI, Gough MJ, Homer-Vanniasinkam S. Risk factor awareness in patients with peripheral arterial disease. J Cardiovasc Surg (Torino). 2007;48:735–740
  25. Willigendael EM, Teijink JA, Bartelink ML, Boiten J, Moll FL, Büller HR, et al. Peripheral arterial disease: public and patient awareness in The Netherlands. Eur J Vasc Endovasc Surg. 2004;27:622–628

PII: S1062-0303(08)00117-9

doi: 10.1016/j.jvn.2008.09.004

Journal of Vascular Nursing
Volume 26, Issue 4 , Pages 118-122 , December 2008

Article Tools